Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19

Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19

Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus. It comprises the angiotensin-converting enzyme type 2 extracellular domain and the human IgG1 Fc fragment.The aim of the study was to carry out a...

Full description

Bibliographic Details
Main Authors: E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, S. A. Grishin, E. I. Trofimets, K. L. Kryshen, L. I. Kozlovskaya, A. S. Lunin, V. D. Apolokhov, S. F. Barbashov, Ya. V. Lavrovsky, M. Yu. Samsonov
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-12-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
sars-cov-2
molnupiravir
rph-137
vero cell culture
syrian hamsters
efficacy
rt-pcr
Online Access:https://www.biopreparations.ru/jour/article/view/437

Internet

https://www.biopreparations.ru/jour/article/view/437

Similar Items